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Mechanism of Action of Ulipristal
Acetate for Emergency
Contraception: A Systematic Review
Elena Rosato*, Manuela Farris and Carlo Bastianelli
Department of Gynecological and Obstetrical Sciences and Urological Sciences, “Sapienza” University of Rome, Rome, Italy
Ulipristal acetate (UPA) is now recommended as first choice hormonal emergency
contraception (EC), due to its higher efficacy and similar safety compared to
Levonorgestrel – EC. Even though all trials demonstrated that the first mechanism
of action is inhibition of ovulation, some authors still postulate that a post fertilization
effect is also possible, raising the alert on medication and fostering the ethical debate.
A Medline database search was performed in order to find recent articles related to
UPA’s effects on ovulation, on fallopian tube and on endometrium. We also analyzed the
effects on sperm function and pregnancy. All studies conclude that UPA is effective in
inhibition of ovulation even when administered shortly before LH peak. The effects on
fallopian tube are unclear: according to some authors UPA inhibits ciliar beat through
an agonistic effect on progesterone receptors, according to others it antagonizes the
progesterone-induced ciliar beat decrease. Concerning the action on endometrium and
on embryo implantation most of the studies concluded that low dose UPA used for
EC has no significant effect on the decrease of endometrial thickness and on embryo’s
attachment, but these results are still matter of debate. Finally recent evidence suggests
that UPA modulates human sperm functions while it has no effect on established
pregnancy. To date the majority of the evidence concurs in excluding a post-fertilization
effect of UPA, even though more studies are needed to clarify its mechanism of action.
Keywords: ulipristal acetate, emergency contraception, ovulation, endometrium, embryo implantation, fallopian
tube
INTRODUCTION
To date, three hormonal methods and the use of a copper intrauterine device are available
worldwide for emergency contraception (EC), while the use of a fourth hormonal method (low
dose mifepristone 10–25 mg) is available only in Armenia, China, Russia, and Vietnam.
First available hormonal EC pills were based on existing combined oral contraceptives
preparations, containing ethinyl estradiol (EE) and levonorgestrel (LNG) administered according
the so-called Yuzpe regimen (Yuzpe et al., 1974).
Then, it has been shown that the LNG at the dose of 1,5 mg alone was both more effective and
better tolerated than the Yuzpe regimen (WHO, 1998).
The World Health Organization (WHO, 1999) pioneered also the trials for using a selective
progesterone receptor modulator (SPRM) for EC. These trials led to the development of a second
generation SPRM, ulipristal acetate (UPA) at the dose of 30 mg. Use of this SPRM for EC was
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authorized by the European Medicines since 2009 in Europe
(EMEA, 2009) and by the US Food and Drug Administration
(FDA) in 2010 and in Asia (US FDA, 2010).
Ulipristal acetate is now recommended as first line treatment
for EC, due to its higher efficacy and a similar rate of side effects
when compared to LNG-EC.
The exact pharmacological mechanism of action of UPA is
still under debate. Even though there is good evidence that the
main mechanism of action is inhibition of ovulation, whereas a
post-fertilization effect has not been shown, some still consider
the latter also possible, raising the alert on medication and
fostering the ethical debate because some religious views consider
fertilization the initial event of human life.
Aim of this review is to collect experimental and clinical
evidence regarding the effects of UPA both before and post
fertilization, in order to refine the ethical debate.
This article reviews UPA’s mechanism of action mainly on
preventing ovulation, on interfering with oocyte or zygote
transport through fallopian tube, and on endometrium
receptivity and embryo implantation. The effects of UPA
on sperm function and pregnancy were also analyzed (Table 1).
PHARMACOKINETICS AND
PHARMACODYNAMICS
Ulipristal acetate is a derivative of 19-norprogesterone. The half-
life after oral intake is 32 h; it binds to plasma proteins for
97–99%, and it is metabolized by the citochrome P450 (Gemzell-
Danielsson et al., 2013a).
Ulipristal acetate depending on the location, the presence
of coactivators or coinhibitors of gene expression, and the
serum levels of progesterone may exert actions of an agonist or
antagonist of progesterone.
The binding capacity to glucocorticoid and androgen
receptors is lower than its antiprogestin activity: UPA shows
in vivo antiglucocorticoid and antiandrogen activity only at
doses 50-fold higher than those needed for antiprogestin effect
(Gemzell-Danielsson and Meng, 2010).
EFFECTS ON OVULATION
In the follicular phase of menstrual cycle the gonadotropins
(LH e FSH) levels increase. FSH promotes the differentiation
of primary follicle to secondary follicle and acts on the
granulosa cells stimulating them to convert testosterone into
estradiol (E2), which is released to support the follicle’s
growth.
In the pre-ovulatory phase estradiol levels increase and
stimulate hypothalamus resulting an increased secretion of LH.
In particular estrogens exert a positive feedback stimulating
de novo progesterone synthesis within the hypothalamus to
trigger the LH surge (Micevych and Sinchak, 2011). The LH surge
acts on theca cells by stimulating the proteolytic activity resulting
in follicular rupture. Ovulation typically occurs 13 to 16 h after
the LH peak and 24–26 h after the estradiol peak. The short fertile
window typically begins 5 days before, through ovulation, and
concludes 1 day after ovulation.
In the initial phases of clinical development (phase I and II)
two studies analyzed various pharmacodynamic effects of UPA
(kwon as CDB-2914) on ovulation blockade, at different stages of
the follicular phase.
When administered in mid follicular phase it has been shown
that a single dose of 10–50–100 mg of UPA, with a follicle’s
diameter of 14–16mm, causes a dose-dependent delay in the time
interval from treatment to follicular rupture and a suppression of
E2. At higher doses, the lead follicle stopped it’s grow and was
replaced by a new lead follicle (Stratton et al., 2000).
On the other hand, if administered when the size of the leading
follicle was ≥18 mm, follicular rupture failed to occur within 5
to 6 days following treatment in 59% of cycles. The block/delay
ovulation occurred in 100% of women with very low LH levels,
and in 79% of women with increasing LH levels. The ovulation’s
blockade has not occurred in the group of women where LH was
at its peak (Brache et al., 2010).
Compared to LNG there are significant differences. An early
study (Croxatto et al., 2004) demonstrated that when the follicle
reaches 18–20mm, ovulation is prevented by LNG in only 12% of
cycles (compared with 13% in the placebo group). More recently
(Brache et al., 2013), it was shown that, at the time of the LH
surge, UPA is more effective than LNG and placebo (UPA 79%,
LNG 14%, and placebo 10%).
This demonstrates that UPA is effective even when
administered shortly before ovulation, when the LH surge
has started, a time period when LNG-CE is no longer effective
(Jamin, 2015).
The ability of UPA to inhibit ovulation even when it is
given just before ovulation is crucial because the probability of
conception is the highest (Wilcox et al., 2004) and is due to the
particular properties of this SPRM: when progesterone levels are
low it acts as an agonist compound, but when they rise, it behaves
as an antagonist by blocking the ascent of LH and therefore the
ovulatory peak. UPA treatment prevents ovulation presumably
by repressing expression of PR-dependent genes critical for
ovulation (Nallasamy et al., 2013). When the LH reaches its
peak it becomes insensitive to the progesterone’s feedback and to
UPA.
This antagonist effect of UPA on PR, has been confirmed
by a recent study (Brache et al., 2015) suggesting that initiating
desogestrel (DSG) treatment the day after UPA significantly
reduced the ovulation delaying effect of UPA.
EFFECTS ON THE FALLOPIAN TUBE
The fallopian tube plays an important role in human conception.
Fertilization normally occurs in the ampullary region of the tube
within 24 h after ovulation. Both muscular contractions and
cilia activity in the human fallopian tube are involved in the
transportation of zygote.
Too rapid or too slow zygote’s tubal transport could cause
desynchronization between the zygote itself and the fallopian
tube, and/or the blastocyst and the endometrium.
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Some studies have suggested that progesterone may suppress
ciliary beating frequency (CBF) and muscular contraction in
the fallopian tube: cilia beat significantly slower after treatment
with high doses of progesterone (Wanggren et al., 2008).
Similar results were shown by a recent study indicating that
LNG decreases the CBF in vitro and in vivo (Zhao et al.,
2015).
The action of the UPA on the fallopian tube has been
investigated in two recent in vitro studies.
In the first study (Li et al., 2014), authors demonstrate that
UPA inhibits CBF and muscular contraction of the fallopian tube
at the pharmacological dose, probably through an agonistic effect
on the tubal PR. Based on these results, the authors postulated
that UPA:
- exerts an agonistic effect on PR in the fallopian tube on the PR-
A isoform, but partial agonist/antagonist activity on the PR-B
isoform (Leo and Lin, 2008). It has also been hypothesized,
as shown in mouse model, an agonistic action of UPA in the
fallopian tube in contrast to the antagonistic action at the ovary
(Teilmann et al., 2006).
- up-regulates mRNA expression of the PR (both generic and
specific to PR-B).
- down-regulates andrenomedullin, which plays an important
role in enhancing the CBF and muscle contraction tone,
amplitude, and frequency in fallopian tube (Li et al., 2010).
According to these finding, UPA should increase the risk
of ectopic pregnancy, inhibiting tubal function. In contrast to
this, no evidence has been shown an increased risk of ectopic
pregnancy with the use of UPA for EC (Levy et al., 2014). It should
be stressed that the development of an ectopic pregnancy may
not be solely explained by delayed embryo transport, but has to
be accompanied by an altered tubal environment and/or embryo
factors to result in tubal implantation (Shaw et al., 2010).
In contrast Yuan et al. (2015) showed that UPA does
not directly affect CBF or the ultrastructure of the cilia,
but it dose-dependently antagonized the progesterone-induced
CBF decrease. To prove the hypothesis of a progesterone
antagonist action the authors highlighted that: Mifepristone,
an antagonist of the PR, inhibits progesterone-induced CBF
reduction (Mahmood et al., 1998); UPA has been shown to be
a progesterone antagonistic without agonistic activity in most
studied published (Attardi et al., 2002; Chabbert-Buffet et al.,
2005; Xu et al., 2008; Communal et al., 2012; Ko et al., 2014) and
finally, their study demonstrates that UPA is able to up-regulate
the expression levels of the estrogen receptor (ER) and the PR
in the fallopian tubes, while progesterone down regulates them
(Horne et al., 2009).
EFFECTS ON ENDOMETRIAL
RECEPTIVITY AND EMBRYO
ATTACHMENT
During the luteal phase, the corpus luteum stimulates the
production of progesterone which creates favorable conditions
for the implantation of the fertilized egg in the endometrium,
consisting in accumulation of glycogen and lipid granules in the
cytoplasm of stromal cells (decidual transformation).
While the effects of UPA on ovulation are well recognized, the
controversy arises on its action on endometrium receptivity, in
contrast with LNG, on which there is a unanimous opinion in
believing that it has no effect on implantation (Lalitkumar et al.,
2007; Meng et al., 2009; Palomino et al., 2010).
When in her pre-ovulatory study Brache reported that the
effects of UPA at the LH peak are null (Brache et al., 2010), some
authors (Mozzanega et al., 2013) pointed out that, if UPA has no
effect on the LH peak, it should not have any effects two days
before ovulation, in contradiction with the conclusive statement
of the paper and therefore the very high UPA’s effectiveness in
preventing pregnancies which does not decrease with the time
elapsed from unprotected intercourse (Fine et al., 2010; Glasier
et al., 2010) should be explained by a post-fertilization effect.
There are two major early clinical phase studies on the
postovulatory effects of UPA.
In the first (Stratton et al., 2010), the authors comparing
early luteal phase treatment with placebo, 10, 50, 100 mg
unmicronized UPA showed that UPA caused a significant dose-
dependent decrease in endometrial thickness: a significant delay
in endometrial maturation was seen in the 50 and 100 mg group
compared to placebo and the 10 mg group upon biopsy four to
6 days after ovulation.
On the basis of these results, (Gemzell-Danielsson et al.,
2013a,b, 2014) in several subsequent reviews concludes that low
dose UPA (30 mg) as used for EC has no significant effect on
endometrium.
Some authors (Glasier et al., 2010; Hillemanns and Hepp,
2013; Mozzanega et al., 2013) confuted that the 50 mg UPA
tablet used in the early luteal phase study involves a significant
reduction in endometrial thickness, and it is pharmacokinetically
identical to the 30 mg micronized formulation used in
the EC.
The second luteal phase study (Passaro et al., 2003) shows that
intake of UPA at different doses in the late luteal phase has no
effect on menstrual cycle length for doses from 10 to 100 mg.
More recently, a study of the endometrial morphology with
UPA taken continuously (13 weeks) at lower doses (5 or 10 mg),
was carried out in a group of patients with uterine myomas
(Williams et al., 2012). Following treatment, the glandular
epithelium appeared inactive, the glandular architecture was
altered and abnormal stromal vessels were also often observed
(the so called PRM-associated endometrial changes PAEC).
In a similar study (Donnez et al., 2012), at 13 weeks of
treatment with different doses of UPA the mean endometrial
thicknesses was 9.4 mm in the group receiving 5 mg and 10.7 mm
in the group receiving 10 mg. The PAEC were observed in the
same percentage of women receiving 5 mg or 10 mg UPA.
Finally, the effect of UPA on human implantation has
been extensively studied utilizing an in vitro three-dimensional
endometrial model. With this in vitro model, it was shown
(Berger et al., 2015) that there is no significant difference in the
attachment of embryos following treatment with UPA compared
with controls and no observable degenerative changes in the
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embryos. Moreover it was found that the level of genes of
several factors believed to be vital for embryo implantation
remain unaltered in the endometrial construct after exposure
to UPA.
EFFECTS ON HUMAN SPERM
FUNCTION
In their transit in female reproductive tract, spermatozoa are
exposed to increased levels of progesterone secreted by the
cumulus cells and the corpus luteum. Progesterone in human
follicular fluid is essential for acrosome reaction induction,
permitting calcium influx into spermatozoa.
Initially (Munuce et al., 2012) it was reported that UPA
does not modify sperm capacitation, nor induce acrosome
reaction (no agonist effect on PR) or prevent human follicular
fluid induced acrosomal reaction (no antagonist effect on
PR).
A more recent study (Ko et al., 2014) has shown that
UPA dose-dependently suppressed progesterone-induced
acrosome reaction, hyperactivation, and calcium concentration
in spermatozoa, concluding that UPA modulate human sperm
functions by acting as progesterone antagonists.
In contrast to UPA, in vitro (Brito et al., 2005) and in vivo (Do
Nascimento et al., 2007) studies found that LNG at doses used for
EC has no direct effect on sperm function.
EFFECTS ON PREGNANCY
In a post marketing experience on more than 1 million women
(Levy et al., 2014) 376 pregnancies have been observed. Of the
232 with a known outcome, 28 ended with live births, 34 were
miscarriages, 151 induced abortions, 4 ectopic pregnancies, and
15 which are still ongoing.
The observed rate of miscarriages and ectopic pregnancy were
not increased when compared with the rate observed in the
general population.
DISCUSSION AND CONCLUSION
Several studies provide strong direct evidence that both UPA
and LNG act by preventing or delaying ovulation. The difference
between the effects of UPA and LNG on ovulation is in their
window of action. When the follicular size is >18 mm, LNG
is unable to prevent ovulation while UPA acts until before
the LH peak immediately before ovulation (Brache et al.,
2013).
Those that advocate a post fertilization effect of UPA stress that
its effectiveness in preventing pregnancies is very high, although
it is taken in proximity of ovulation. On this regard, some key
points need to be considered.
Firstly, the published articles on the postovulatory effects UPA
rely on already published studies and not on new in vitro/vivo
studies. Moreover in many of these debates, there is not a clear
distinction between the time of ovulation and the time of sexual
intercourse. The “5 days after” refers to sexual intercourse event
and not to the time of ovulation. This could be considered as
the same kind of miswording which referred to LNG-EC as
“the day after” pill. On this subject, some authors (Hillemanns
and Hepp, 2013) sustain that when unprotected intercourse
occurs for example 12 h after ovulation and UPA is taken
“5 days later,” then UPA must have other effects than delaying
ovulation.
Secondly, in studies on UPA effects on the fallopian tube (Li
et al., 2014; Yuan et al., 2015) is unclear how it affects fertilization
and /or transport of the fertilized egg and therefore the embryo
implantation.
Thirdly, the authors that showed an endometrial suppression
after treatment with the same SPRM utilized for treatment of
myomas (Williams et al., 2012) did not demonstrate that this is
also true for the UPA dosage utilized for EC.
Finally, the abortifacient role of Mifepristone (“RU-486”), at
higher doses, could influence negatively the attitude toward same
family compounds. The drug is approved for use in combination
with misoprostol in a number of countries to terminate a
pregnancy, given at the dose of 200–600 mg which is 8- to 60-fold
greater than the dose used for EC (WHO, 2012).
On the other hand, it should be pointed out that the exact
mechanism of action of UPA is not completely clarified. In
particular it is still poorly understood when it acts as agonist or
antagonist of progesterone. Knowledge of its precise mechanism
of action would be helpful to better understand its effects on
target organs.
If there would be a method of identifying fertilization, it could
have been the only way to show if UPA acts in the early phase
of the zygote, but attempts to identify a molecule that could
operate as a early marker of fertilization have not be successful.
In particular a protein called the “early pregnancy factor” (EPF)
was first described in mice as an immunosuppressive agent
(Morton et al., 1974) and subsequently identified in additional
species and humans (Morton et al., 1982; Tinneberg et al.,
1984). The biological features of EPF suggest an opportunity
for early pregnancy diagnosis: it could be, in the future, a
marker to verify UPA’s mechanism of action (Hatzel et al.,
2015).
The ethical problem arises in considering the possibility of
its putative post fertilization effect, based on the assertion that it
causes abortion.
By definition, contraception comprises all methods capable
of preventing pregnancy as defined by the WHO. Accepting
this definition, hormonal EC includes all methods acting
after intercourse, but before implantation. To date, the
mechanism of action appears rather related to postponing
ovulation, having an effect on sperm function while no
effect on endometrium has been shown at clinically relevant
doses.
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